Covid-19 vaccine Covaxin, developed by India entered the third phase of the trial on Friday
The globally confirmed Covid-19 cases reached 58,095,887 on Sunday with 1,379,83 deaths, according to data compiled by Johns Hopkins University (JHU).
The US remains the worst-hit country with 12,088,409 cases, including 255,833 fatalities as of Sunday.
Brazil registered 376 new deaths from Covid-19, bringing the national death toll to 168,989, the government said Saturday. The number of infections went up by 32,622, pushing the nationwide tally to 6,052,786.
Neighbouring India's Covid-19 tally reached 9,095,806 on Sunday as 45,209 new cases were registered in the past 24 hours, the health ministry said.
The country’s death toll mounted to 133,227 as 501 more patients died since Saturday morning.
India currently has 440,962 active cases, while 8,521,617 patients have been discharged from hospitals.
The government is ramping up Covid-19 testing facilities across the country. Till Saturday, a total of 131,733,134 tests were conducted, out of which 1,075,326 tests were conducted on Saturday alone, said the figures released by the Indian Council of Medical Research (ICMR) on Sunday.
Meanwhile, Covid-19 vaccine Covaxin, which is being developed by India's biotechnology company "Bharat Biotech International Limited," entered the third phase of the trial on Friday.
Bangladesh’s Covid-19 situation
Bangladesh saw a rise in deaths from Covid-19 infections as health authorities reported 28 more deaths in 24 hours until Saturday, taking the fatalities to 6,350 with a death rate of 1.43%.
During this period, 1,848 new cases were detected, bringing the caseload to 445,281.
So far, 360,352 patients – 80.93% have recovered, including 1,921 in the last 24 hours
Bangladesh reported its first cases on March 8. The infection number reached the 300,000 mark on August 26. The first death was reported on March 18 and the death toll crossed 6,000 on November 4.